Johnson & Johnson (JNJ) Receives $133.02 Consensus PT from Analysts

Shares of Johnson & Johnson (NYSE:JNJ) have received a consensus recommendation of “Hold” from the twenty-one ratings firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $133.79.

JNJ has been the topic of several research analyst reports. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research note on Monday. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. UBS AG reiterated a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research note on Thursday, August 31st. Finally, Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th.

In related news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Harding Loevner LP purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.7% in the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares during the period. Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares during the period. 65.90% of the stock is currently owned by institutional investors.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 1.48% during midday trading on Friday, hitting $133.22. The company had a trading volume of 8,705,535 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The firm has a market capitalization of $357.56 billion, a P/E ratio of 22.54 and a beta of 0.79. The stock has a 50 day moving average price of $132.79 and a 200 day moving average price of $129.43.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.74 EPS. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.76%.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Receives $133.02 Consensus PT from Analysts” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.chaffeybreeze.com/2017/09/20/johnson-johnson-jnj-receives-133-02-consensus-pt-from-analysts.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply